EUVIMEDOpdag EUVIMED
Kontrollierte klinische Studie

Antiviral Treatment of Calves Persistently Infected with Bovine Viral Diarrhoea Virus

Benjamin W Newcomer, M Shonda Marley, Patricia K Galik, Paul H Walz, Yijing Zhang, Kay P Riddell, Christine C Dykstra, David W Boykin, Arvind Kumar, Crisanta Cruz-Espindola, Dawn M Boothe, Kellye S Joiner and 1 more

Antiviral Chemistry and Chemotherapy · 2012-02 · 22 (4) · 171-179

DOI: 10.3851/imp1903 ↗

At a glance

Kontrollierte klinische Studie in Antiviral Chemistry and Chemotherapy, published online on 2012-02-01. Written by Benjamin W Newcomer and 12 co-authors. Institution: Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, USA. bwn0001@auburn.edu. Cited 19 times so far (Crossref); 27 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Animals persistently infected (PI) with bovine viral diarrhoea virus (BVDV) are a key source of viral propagation within and among herds. Currently, no specific therapy exists to treat PI animals. The purpose of this research was to initiate evaluation of the pharmacokinetic and safety data of a novel antiviral agent in BVDV-free calves and to assess the antiviral efficacy of the same agent in PI calves.

Methods

One BVDV-free calf was treated with 2-(2-benzimidazolyl)-5-[4-(2-imidazolino)phenyl]furan dihydrochloride (DB772) once at a dose of 1.6 mg/kg intravenously and one BVDV-free calf was treated three times a day for 6 days at 9.5 mg/kg intravenously. Subsequently, four PI calves were treated intravenously with 12 mg/kg DB772 three times a day for 6 days and two PI control calves were treated with an equivalent volume of diluent only.

Results

Prior to antiviral treatment, the virus isolated from each calf was susceptible to DB772 in vitro. The antiviral treatment effectively inhibited virus for 14 days in one calf and at least 3 days in three calves. Subsequent virus isolated from the three calves was resistant to DB772 in vitro. No adverse effects of DB772 administration were detected.

Conclusions

Results demonstrate that DB772 administration is safe and exhibits antiviral properties in PI calves while facilitating the rapid development of viral resistance to this novel therapeutic agent.

Subjects

MeSH terms (MEDLINE)

AnimalsAntiviral AgentsBenzimidazolesBovine Virus Diarrhea-Mucosal DiseaseCattleDiarrhea Viruses, Bovine ViralDose-Response Relationship, DrugDrug Resistance, ViralFuransMicrobial Sensitivity TestsOsmolar ConcentrationTime Factors

Substances

2-(2-benzimidazolyl)-5-(4-(2-imidazolino)phenyl)furanAntiviral AgentsBenzimidazolesFurans

Authors and institutions

  • Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, USA. bwn0001@auburn.edu

Cite

APA

Newcomer, B. W., Marley, M. S., Galik, P. K., Walz, P. H., Zhang, Y., Riddell, K. P., Dykstra, C. C., Boykin, D. W., Kumar, A., Cruz-Espindola, C., Boothe, D. M., Joiner, K. S., & Givens, M. D. (2012). Antiviral Treatment of Calves Persistently Infected with Bovine Viral Diarrhoea Virus. Antiviral Chemistry and Chemotherapy, 22(4), 171-179. https://doi.org/10.3851/imp1903

Vancouver

Newcomer BW, Marley MS, Galik PK, Walz PH, Zhang Y, Riddell KP, et al. Antiviral Treatment of Calves Persistently Infected with Bovine Viral Diarrhoea Virus. Antiviral Chemistry and Chemotherapy. 2012;22(4):171-179. doi:10.3851/imp1903

BibTeX
@article{Newcomer2012,
  author = {Newcomer, Benjamin W and Marley, M Shonda and Galik, Patricia K and Walz, Paul H and Zhang, Yijing and Riddell, Kay P and Dykstra, Christine C and Boykin, David W and Kumar, Arvind and Cruz-Espindola, Crisanta and Boothe, Dawn M and Joiner, Kellye S and Givens, M Daniel},
  title = {Antiviral Treatment of Calves Persistently Infected with Bovine Viral Diarrhoea Virus},
  journal = {Antiviral Chemistry and Chemotherapy},
  year = {2012},
  volume = {22},
  number = {4},
  pages = {171--179},
  doi = {10.3851/imp1903}
}
Start for free →